The prognostic value of EGFR amplification and/or overexpression in GBM remains controversial, since some studies support that that EGFR is a poor prognosis factor [200], and others that there is no relationship between EGFR levels and glioma evolution [201]. This evidence concerns the gene EGFR and central nervous system cancer.